全文获取类型
收费全文 | 369篇 |
免费 | 35篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 3篇 |
妇产科学 | 3篇 |
基础医学 | 56篇 |
口腔科学 | 5篇 |
临床医学 | 27篇 |
内科学 | 130篇 |
皮肤病学 | 2篇 |
神经病学 | 33篇 |
特种医学 | 22篇 |
外科学 | 36篇 |
综合类 | 3篇 |
预防医学 | 15篇 |
眼科学 | 4篇 |
药学 | 39篇 |
肿瘤学 | 26篇 |
出版年
2023年 | 16篇 |
2022年 | 2篇 |
2021年 | 14篇 |
2020年 | 14篇 |
2019年 | 15篇 |
2018年 | 26篇 |
2017年 | 10篇 |
2016年 | 14篇 |
2015年 | 13篇 |
2014年 | 19篇 |
2013年 | 26篇 |
2012年 | 43篇 |
2011年 | 46篇 |
2010年 | 18篇 |
2009年 | 9篇 |
2008年 | 18篇 |
2007年 | 18篇 |
2006年 | 17篇 |
2005年 | 19篇 |
2004年 | 14篇 |
2003年 | 9篇 |
2002年 | 9篇 |
2001年 | 3篇 |
2000年 | 2篇 |
1999年 | 1篇 |
1998年 | 1篇 |
1997年 | 3篇 |
1975年 | 1篇 |
1974年 | 2篇 |
1973年 | 1篇 |
1969年 | 1篇 |
1967年 | 1篇 |
排序方式: 共有405条查询结果,搜索用时 46 毫秒
1.
Tjalf Ziemssen Ovidiu A. Bajenaru Adriana Carrá Nina de Klippel João C. de Sá Astrid Edland Jette L. Frederiksen Olivier Heinzlef Klimentini E. Karageorgiou Rafael H. Lander Delgado Anne-Marie Landtblom Miguel A. Macías Islas Niall Tubridy Yossi Gilgun-Sherki 《Journal of neurology》2014,261(11):2101-2111
Studies suggest that patients with relapsing-remitting multiple sclerosis (RRMS) who do not benefit from other disease-modifying treatments (DMTs) may benefit from converting to glatiramer acetate (GA). COPTIMIZE was a 24-month observational study designed to assess the disease course of patients converting to GA 20 mg daily from another DMT. Eligible patients had converted to GA and had received prior DMT for 3–6 months, depending on the reasons for conversion. Patients were assessed at baseline and at 6, 12, 18, and 24 months. In total, 672 patients from 148 centers worldwide were included in the analysis. Change of therapy to GA was prompted primarily by lack of efficacy (53.6 %) or intolerable adverse events (AEs; 44.8 %). Over a 24-month period, 72.7 % of patients were relapse free. Mean annual relapse rate decreased from 0.86 [95 % confidence interval (CI) 0.81–0.91] before the change to 0.32 (95 % CI 0.26–0.40; p < 0.0001) at last observation, while the progression of disability was halted, as the Kurtzke Expanded Disability Status Scale (EDSS) scores remained stable. Patients improved significantly (p < 0.05) on measures of fatigue, quality of life, depression, and cognition; mobility scores remained stable. The results indicate that changing RRMS patients to GA is associated with positive treatment outcomes. 相似文献
2.
Pressure ulcer prevention is an important long‐term care (LTC) quality indicator. While the Braden Scale is a recommended risk assessment tool, there is a paucity of information specifically pertaining to its validity within the LTC setting. We, therefore, undertook a systematic review and meta‐analysis comparing Braden Scale predictive and concurrent validity within this context. We searched the Medline, EMBASE, PsychINFO and PubMed databases from 1985–2014 for studies containing the requisite information to analyze tool validity. Our initial search yielded 3,773 articles. Eleven datasets emanating from nine published studies describing 40,361 residents met all meta‐analysis inclusion criteria and were analyzed using random effects models. Pooled sensitivity, specificity, positive predictive value (PPV), and negative predictive values were 86%, 38%, 28%, and 93%, respectively. Specificity was poorer in concurrent samples as compared with predictive samples (38% vs. 72%), while PPV was low in both sample types (25 and 37%). Though random effects model results showed that the Scale had good overall predictive ability [RR, 4.33; 95% CI, 3.28–5.72], none of the concurrent samples were found to have “optimal” sensitivity and specificity. In conclusion, the appropriateness of the Braden Scale in LTC is questionable given its low specificity and PPV, in particular in concurrent validity studies. Future studies should further explore the extent to which the apparent low validity of the Scale in LTC is due to the choice of cutoff point and/or preventive strategies implemented by LTC staff as a matter of course. 相似文献
3.
4.
5.
Qin Y Xu J Aysola K Oprea G Reddy A Matthews R Okoli J Cantor A Grizzle WE Partridge EE Reddy ES Landen C Rao VN 《American journal of cancer research》2012,2(5):540-548
Mutation in the BRCA1 gene is associated with increased risk for hereditary breast and ovarian cancers. In sporadic ovarian tumors, BRCA1 dysfunction is thought to be common. BRCA1 is a nuclear-cytoplasm shuttling protein. Our group has previously reported that BRCA1 proteins, unlike K109R and cancer-predisposing mutant C61G BRCA1 proteins, bind the sole SUMO E2-conjugating enzyme Ubc9. In this study, we examined the result of altered Ubc9 binding and knockdown on the sub-cellular localization and growth inhibitory function of BRCA1 proteins in ovarian cancer cells. Using live imaging of YFP, RFP-tagged BRCA1 and BRCA1a proteins, our results show enhanced cytoplasmic localization of K109R and C61G mutant BRCA1 proteins in ES-2, NIHOVCAR3 and UWB 1.289 ovarian cancer cells. Down-regulation of Ubc9 in ovarian cancer cells using Ubc9 siRNA resulted in cytoplasmic localization of BRCA1 and BRCA1a proteins. These mutant BRCA1a proteins were impaired in their capacity to inhibit growth of ES-2 ovarian cancer cells. Several ovarian cancer cells, including a BRCA1-null ovarian cancer cell line, showed higher levels of expression of Ubc9. This is the first study demonstrating the physiological link between loss of Ubc9 binding and loss of growth suppression of disease-associated mutant BRCA1a proteins in ovarian cancer cells. BRCA1, by turning off or on Ubc9 binding, regulates growth of ovarian cancers. 相似文献
6.
Epidemiology and one‐year outcomes in patients with chronic heart failure and preserved,mid‐range and reduced ejection fraction: an analysis of the ESC Heart Failure Long‐Term Registry 下载免费PDF全文
Ovidiu Chioncel Mitja Lainscak Petar M. Seferovic Stefan D. Anker Maria G. Crespo‐Leiro Veli‐Pekka Harjola John Parissis Cecile Laroche Massimo Francesco Piepoli Candida Fonseca Alexandre Mebazaa Lars Lund Giuseppe A. Ambrosio Andrew J. Coats Roberto Ferrari Frank Ruschitzka Aldo P. Maggioni Gerasimos Filippatos 《European journal of heart failure》2017,19(12):1574-1585
7.
Malene Winther Michael Gabl Tudor I. Oprea Bodil J?nsson Francois Boulay Johan Bylund Claes Dahlgren Huamei Forsman 《Antimicrobial agents and chemotherapy》2014,58(5):2985-2988
Pepducins containing a fatty acid linked to an amino acid sequence derived from cytosolic parts of a G-protein-coupled receptor (GPCR) constitute a new group of lipopeptide tools in GPCR studies. Pepducins corresponding to the third intracellular loop of formyl peptide receptor 2 (FPR2) activate human neutrophils, and we show here that, in addition, these allosteric modulators of receptor activity also kill bacteria. The functional dualism of FPR2 pepducins could potentially be explored as a novel class of antibacterial drugs with immunomodulatory properties. 相似文献
8.
Ioana Vlad Jason Armstrong James Ridgley Ovidiu Pascu 《Clinical toxicology (Philadelphia, Pa.)》2016,54(3):286-289
Context: Dabigatran etexilate (dabigatran) is a direct thrombin inhibitor anticoagulant agent. There is limited information about the changes in coagulation profile and outcomes in overdose. A monoclonal antibody has been developed to neutralize the anticoagulant effect of dabigatran. Case reports describe enhanced clearance of dabigatran by haemodialysis as an intervention to prevent haemorrhagic complications – however, the threshold for initiating haemodialysis is not well defined in an asymptomatic patient with normal renal function. Case details: Two patients presented following deliberate dabigatran overdoses. A 55-year-old woman ingested 10?×?150?mg dabigatran. A 21-year-old woman with a history of systemic lupus erythematosus and pulmonary embolus ingested 100?×?110?mg dabigatran. Both were admitted to the intensive care unit and managed expectantly. Serial coagulation tests normalized over 60 h. The half-life of dabigatran was not prolonged following overdose, being calculated between 7 and 11 h in each case. There was positive correlation between international normalized ratio (INR), prothrombin time (PT) and activated partial thromboplastin time (aPTT) with plasma dabigatran levels. Conclusion: There is limited experience with dabigatran overdoses. Normal aPTT, PT and INR assays 12 h following deliberate ingestion indicate that the drug concentration is not high. Individual risk assessment of bleeding risk needs to be formulated for each patient and expectant management is reasonable in the presence of normal renal function and absent risk factors for bleeding. 相似文献
9.
John R. Teerlink Beth A. Davison Gad Cotter Aldo P. Maggioni Naoki Sato Ovidiu Chioncel Georg Ertl G. Michael Felker Gerasimos Filippatos Barry H. Greenberg Peter S. Pang Piotr Ponikowski Christopher Edwards Stefanie Senger Sam L. Teichman Olav Wendelboe Nielsen Adriaan A. Voors Marco Metra 《European journal of heart failure》2020,22(2):315-329
10.
Ovidiu Chioncel John Parissis Alexandre Mebazaa Holger Thiele Steffen Desch Johann Bauersachs Veli‐Pekka Harjola Elena‐Laura Antohi Mattia Arrigo Tuvia B. Gal Jelena Celutkiene Sean P. Collins Daniel DeBacker Vlad A. Iliescu Ewa Jankowska Tiny Jaarsma Kalliopi Keramida Mitja Lainscak Lars H Lund Alexander R. Lyon Josep Masip Marco Metra Oscar Miro Andrea Mortara Christian Mueller Wilfried Mullens Maria Nikolaou Massimo Piepoli Susana Price Giuseppe Rosano Antoine Vieillard‐Baron Jean M. Weinstein Stefan D. Anker Gerasimos Filippatos Frank Ruschitzka Andrew J.S. Coats Petar Seferovic 《European journal of heart failure》2020,22(8):1315-1341
Cardiogenic shock (CS) is a complex multifactorial clinical syndrome with extremely high mortality, developing as a continuum, and progressing from the initial insult (underlying cause) to the subsequent occurrence of organ failure and death. There is a large spectrum of CS presentations resulting from the interaction between an acute cardiac insult and a patient's underlying cardiac and overall medical condition. Phenotyping patients with CS may have clinical impact on management because classification would support initiation of appropriate therapies. CS management should consider appropriate organization of the health care services, and therapies must be given to the appropriately selected patients, in a timely manner, whilst avoiding iatrogenic harm. Although several consensus‐driven algorithms have been proposed, CS management remains challenging and substantial investments in research and development have not yielded proof of efficacy and safety for most of the therapies tested, and outcome in this condition remains poor. Future studies should consider the identification of the new pathophysiological targets, and high‐quality translational research should facilitate incorporation of more targeted interventions in clinical research protocols, aimed to improve individual patient outcomes. Designing outcome clinical trials in CS remains particularly challenging in this critical and very costly scenario in cardiology, but information from these trials is imperiously needed to better inform the guidelines and clinical practice. The goal of this review is to summarize the current knowledge concerning the definition, epidemiology, underlying causes, pathophysiology and management of CS based on important lessons from clinical trials and registries, with a focus on improving in‐hospital management. 相似文献